0
Editorials |

The 2010 European Society of Cardiology Guidelines on the Management of Atrial Fibrillation: An Evolution or Revolution?

Gregory Y. H. Lip, MD; Jonathan L. Halperin, MD; Hung-Fat Tse, MD, PhD
Author and Funding Information

From the University of Birmingham Centre for Cardiovascular Sciences (Dr Lip), City Hospital; The Cardiovascular Institute (Dr Halperin), Mount Sinai Medical Center; and Cardiology Division (Dr Tse), Department of Medicine, The University of Hong Kong, Queen Mary Hospital.

Correspondence to: Gregory Y. H. Lip, MD, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, England; e-mail: g.y.h.lip@bham.ac.uk


Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Lip has acted as a consultant for Bayer, Astellas, Merck, AstraZeneca, Sanofi-Aventis, BMS/Pfizer, Daiichi, Biotronik, Portola, and Boehringer-Ingleheim and has been on the speakers bureau for Bayer, BMS/Pfizer, Boehringer-Ingelheim, and Sanofi. He was a member of the task force writing the 2010 European Society of Cardiology guidelines on atrial fibrillation. Dr Halperin has received consulting fees from the following pharmaceutical manufacturers for advisory activities involving the development of new anticoagulant drugs for use in patients with atrial fibrillation: Astellas Pharma, US Bayer AG HealthCare, Boehringer-Ingelheim, BMS, Daiichi Sankyo, Johnson & Johnson, Pfizer Inc, and Sanofi-Aventis. He has received travel expenditures in conjunction with industry-sponsored consulting or educational activities. He has received consulting fees from Biotronik Inc as co-chair of the steering committee for the IMPACT clinical trial and is a member of the operations committee for the PALLAS clinical trial sponsored by Sanofi-Aventis. Dr Halperin participates as a speaker in medical education programs supported by unrestricted educational grants from commercial sponsors. He serves as a member of writing committees generating clinical practice guidelines related to the topic of this work. Dr Tse has acted as a consultant for Bayer, BMS/Pfizer, Boehringer-Ingelheim, Sanofi, and St Jude Medical and as national coordinator for the PALLAS clinical trial sponsored by Sanofi.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).


© 2011 American College of Chest Physicians


Chest. 2011;139(4):738-741. doi:10.1378/chest.10-2763
Text Size: A A A
Published online

Extract

At the 2010 European Society of Cardiology (ESC) meeting in Stockholm, Sweden, new European guidelines on the management of atrial fibrillation (AF) were published.1 These guidelines represent a departure from the previous European and American guidelines published in 2006, which the ESC formulated conjointly with the American College of Cardiology and American Heart Association. Do the changes in the new ESC guidelines represent an evolution in practice based on substantial advances in AF management since 2006, or are these guidelines a revolution that deliberately cuts a new path?

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543